SIREN : 847883329
BREST BIO 29 ASSOCIES is a French company founded 7 years ago, specialized in the sector Gestion de fonds. Based in BREST (29200), this company of category PME shows in 2024 a net income negative of -586 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicador | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Ingresos | N/C | N/C | N/C | N/C | N/C | N/C |
| Resultado neto | -586 267 € | 5 224 048 € | -17 971 € | 901 932 € | -3 856 € | 448 415 € |
| EBITDA | -10 476 € | -79 € | -12 040 € | -7 525 € | -3 856 € | -24 196 € |
| Margen neto | N/C | N/C | N/C | N/C | N/C | N/C |
In 2024, BREST BIO 29 ASSOCIES records a net loss of 586 k€. This deficit will reduce equity on the balance sheet.
-10 476 €
-10 289 €
-586 267 €
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 100%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
0.0%
99.929%
0.0
In 2024, the debt ratio of BREST BIO 29 ASSOCIES (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of BREST BIO 29 ASSOCIES (99.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of BREST BIO 29 ASSOCIES (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 8095.64. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
8095.635
-12037.037
In 2024, the liquidity ratio of BREST BIO 29 ASSOCIES (8095.64) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of BREST BIO 29 ASSOCIES (-12037.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 289 days. Excellent situation: suppliers finance 289 days of the operating cycle (retail model).
0 €
0 j
289 j
0 j
Compare BREST BIO 29 ASSOCIES with other companies in the same sector:
The revenue of BREST BIO 29 ASSOCIES is not publicly disclosed (confidential accounts filed with INPI).
BREST BIO 29 ASSOCIES recorded a net loss in 2024.
The headquarters of BREST BIO 29 ASSOCIES is located in BREST (29200), in the department Finistere.
The tax return of BREST BIO 29 ASSOCIES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BREST BIO 29 ASSOCIES operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.